Literature DB >> 7852623

Implants of polymer-encapsulated human NGF-secreting cells in the nonhuman primate: rescue and sprouting of degenerating cholinergic basal forebrain neurons.

D F Emerich1, S R Winn, J Harper, J P Hammang, E E Baetge, J H Kordower.   

Abstract

Baby hamster kidney (BHK) cells were genetically modified to secrete high levels of human nerve growth factor (BHK-hNGF). Following polymer encapsulation, these cells were implanted into the lateral ventricle of four cynomolgus monkeys immediately following a unilateral transection/aspiration of the fornix. Three control monkeys received identical implants, with the exception that the BHK cells were not genetically modified to secrete hNGF and thus differed only by the hNGF construct. One monkey received a fornix transection only. All monkeys displayed complete transections of the fornix as revealed by a comprehensive loss of acetylcholinesterase-containing fibers within the hippocampus ipsilateral to the lesion. Control monkeys that were either unimplanted or received BHK-control (non-NGF secreting) cell implants did not differ from each other and displayed extensive losses of choline acetyltransferase and p75 NGF receptor (NGFr)-immunoreactive neurons within the medial septum (MS; 53 and 54%, respectively) and vertical limb of the diagonal band (VLDB; 21 and 30%, respectively) ipsilateral to the lesion. In contrast, monkeys receiving implants of BHK-hNGF cells exhibited a only a modest loss of cholinergic neurons within the septum (19 and 20%, respectively) and VLDB (7%). Furthermore, only implants of hNGF-secreting cells induced a dense sprouting of cholinergic fibers within the septum, which ramified against the ependymal lining of the ventricle adjacent to the transplant site. Examination of the capsules retreived from monkeys just prior to their death revealed an abundance of cells that produced detectable levels of hNGF in a sufficient concentration to differentiate PC12A cells in culture. These findings support the use of polymer-encapsulated cell therapy as a potential treatment for neurodegenerative diseases such as Alzheimer disease where basal forebrain degeneration is a consistent pathological feature. Moreover, this encapsulated xenogeneic system may provide therapeutically effective levels of a number of neurotrophic factors, alone or in combination, to select populations of neurons within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7852623     DOI: 10.1002/cne.903490110

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  19 in total

Review 1.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

Review 2.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

3.  Position-independent expression of a human nerve growth factor-luciferase reporter gene cloned on a yeast artificial chromosome vector.

Authors:  F A Asselbergs; R Grossenbacher; R Ortmann; B Hengerer; G K McMaster; E Sutter; R Widmer; F Buxton
Journal:  Nucleic Acids Res       Date:  1998-04-01       Impact factor: 16.971

Review 4.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

5.  Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease.

Authors:  D F Emerich; M D Lindner; S R Winn; E Y Chen; B R Frydel; J H Kordower
Journal:  J Neurosci       Date:  1996-08-15       Impact factor: 6.167

6.  NS-417, a novel compound with neurotrophic-like effects.

Authors:  Lone Dagø; Dan Peters; Morten Meyer; Barbara Hartz; Vibeke Kruse; Jørgen Drejer; Mette Grønborg
Journal:  Neurochem Res       Date:  2002-02       Impact factor: 3.996

7.  Millimeter-scale positioning of a nerve-growth-factor source and biological activity in the brain.

Authors:  M J Mahoney; W M Saltzman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

8.  Transplantation of NGF-gene-modified bone marrow stromal cells into a rat model of Alzheimer' disease.

Authors:  Li-Yan Li; Jin-Tao Li; Qing-Ying Wu; Jin Li; Zhong-Tang Feng; Su Liu; Ting-Hua Wang
Journal:  J Mol Neurosci       Date:  2007-12-12       Impact factor: 3.444

Review 9.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

10.  Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene delivery.

Authors:  Alan H Nagahara; Tim Bernot; Rod Moseanko; Laurie Brignolo; Armin Blesch; James M Conner; Anthony Ramirez; Mehdi Gasmi; Mark H Tuszynski
Journal:  Exp Neurol       Date:  2008-10-25       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.